STAT + Boston Globe Investigation

Health By Andrew Joseph and Helen Branswell

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants

Pharmalot By Ed Silverman

Martin Shkreli’s former company pays $40 million for blocking competition for a life-saving drug

Pharmalot By Ed Silverman

Centene agrees to pay $28 million to resolve another state probe into its pharmacy benefits business

Health Tech By Casey Ross and Maddie Bender

Pear makes its stock market debut & telehealth players lock arms

Exclusive By Katie Palmer

‘A multi-decade journey’: Chan Zuckerberg Initiative invests another $3.4 billion to advance scientific tools

Pharmalot By Ed Silverman

Pharmalittle: Glaxo and Vir antibody remains effective against Omicron; Biden talks up drug-pricing reform

Health By Angus Chen and Olivia Goldhill

STAT+ Conversation: The ‘Shroom Boom’

In the Lab By Angus Chen

Is cancer biology research reproducible? After a decade of work, the answer still isn’t clear